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Abstract
Objective: To integrate CT-perfusion into a routine,
clinical contrast-enhanced (ce) PET/CT protocol for the
evaluation of liver metastases and to compare functional
CT and PET parameters.
Materials and methods: Forty-six consecutive patients
(mean age: 60 (34–82) years; 20 f, 26 m) with known liver
lesions (colorectal metastases (n = 34), primary liver
cancer (n = 4), breast cancer (n = 3), anal cancer, gastric
cancer, esophageal cancer, GIST, duodenal cancer (all:
n = 1)whowere referred for staging or therapy follow-up
by [18F]-Fluoro-2-deoxy-D-glucose-positron-emission-
tomography/computed-tomography imaging (FDG-PET/
CT) were included. After acquisition of a low-dose PET/
CT, a split-injection (70–90 mL) ce-CT-protocol, including
a 35-sCT-perfusion scan of the liver and a diagnostic ce-CT
of the thorax and/or abdomen (70 s delay, iv-contrast
volume: 90 mL, 4 mL/s) was performed. CT-perfusion
parameters (BF, BV, MTT,) and semi-quantitative PET-
parameters (SUVmax, SUVmean, TLG, PETvol) were
analyzed and compared.
Results: CT-perfusion data could be obtained in all but
one patient with shallow breathing. In all patients,
diagnostic ce-PET/CT quality was adequate without the
use of additional contrast media. Significant correlations
(P < 0.05) were found for each of BF, BV, MTT, and
SUVmax, further, BF and MTT correlated with TLG.
Several other correlations were seen for other perfusion
and PET-parameters.
Conclusion: Combined CT-perfusion/PET/CT-protocol
without the use of additional contrast media is feasible
and can be easily integrated in clinical routine. Perfusion
parameters and PET-parameters are only partly correlat-
ing and therefore have to be investigated further at fixed
time points during the course of disease and therapy.
Key words: PET/CT—CT-perfusion—Liver
metastases—PET/CT-perfusion—Oncological imaging
Computed-tomography perfusion (CT-perfusion) is a
robust, non-invasive technique, which has been primarily
invented for brain perfusion and now has found its way
also into perfusion of different tumors of the body [1–6].
It uses the enhancement pattern of contrast media over
time to determine different perfusion parameters, which
already provided effective measurements in humans and
animal experiments for evaluation of tumor angiogenesis
and antivascular chemotherapy [3, 4, 7–10]. To date, it
has been only partly integrated in a clinical routine and
perfusion results are still under investigation concerning
their clinical impact. However, based on the increasing
availability of multi-slice scanner and easy-to-use soft-
ware for perfusion evaluation, there is increasing interest
in such perfusion data.
[18F]-Fluoro-2-deoxy-D-glucose-positron-emission-
tomography/computed-tomography imaging (FDG-
PET/CT) on the other side is currently one of the most
used oncological staging and therapy follow-up tech-
niques and is worldwide used and reimbursed for a wide
variety of cancers [11–15]. It overcomes the classical
limitation of a single-entity approach and serves as a
valuable tool in clinical routine for therapy decision [16].
However, FDG—by far the most commonly used tracer
in oncological PET/CT-imaging—provides information
about viability of the cell but no information aboutCorrespondence to: Patrick Veit-Haibach; email: patrick.veit@gmx.de
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blood flow (BF) parameters, which are considered
especially important in different therapy evaluation
trials.
The aim of this feasibility study was ﬁrst: to integrate
CT-perfusion into a routine, clinical, intravenous con-
trast-enhanced PET/CT protocol (ce-PET/CT) for the
evaluation of liver metastases; second: to compare and to
correlate CT-perfusion parameters (BF, blood volume
(BV), and mean transit time (MTT)) and semi-quanti-
tative PET-parameters (SUVmax, SUVmean, tumor
lesion glycolysis (TLG) volume of the lesion (PETvol)) in
our patient population.
Materials and methods
Patients
The study population consisted of 46 consecutively in-
cluded patients (mean age: 60 years; range: 34–82 years;
20 female, 26 male) with known or highly suspected liver
lesions who were referred for staging or therapy follow-
up by FDG-PET/CT. No further selection was applied to
the patient population. Thirty-four patients had a history
of a colon/rectal cancer. In this subgroup, 18 patients
were pre-therapeutic and 16 patients had chemotherapy
within the last 2 month (post-therapy). Nine of those
patients received standard chemotherapy (FOLFOX,
FOLFIRI), seven patients received additional antivas-
cular therapy (Bevacizumab/Cetuximab). Another four
patients had a history of a primary liver cancer, three
patients had metastases of a breast cancer, ﬁve patients
had different singular cancers (one anal cancer, one
gastric cancer, one esophageal cancer, one gastro-intes-
tinal stromal tumor, and one duodenal carcinoma). On
average, the patients had 3.8 metastases (range: 1–12
metastases), the mean size was 2.7 cm (range: 1.5–7 cm).
None of the patients suffered from a known abdom-
inal inﬂammatory disease. In all patients, the primary
tumor was histologically veriﬁed, in the majority of
cases, at least one of the liver lesions was histologically
veriﬁed, also. The study was performed in accordance
with the regulations of the local institutional review
board and ethics committee. Written, informed consent
was obtained from all patients before the examination
and enrollment into the study.
Integrated FDG-PET/CT imaging
All data were acquired on a combined PET/CT in-line
system (Discovery VCT, GE Healthcare, Milwaukee,
WI, USA). These dedicated systems integrate a last-
generation, full-ring PET scanner with a multislice helical
64-slice-CT scanner and permit the acquisition of
co-registered CT and PET images in one imaging pro-
cedure. The patients were instructed to fast for 4 h prior
to the examination. PET/CT-imaging with integrated
CT-perfusion was started 60 min after the injection of a
standard dose of 340–370 MBq 18F-FDG. Blood sugar
level was determined prior to the injection of the FDG
(range, 80–120 mg/dL, 4.4–6.7 mmol/L). In addition, an
oral CT-contrast agent (30 mL Gastrograﬁn; Bayer
Schering Pharma, Berlin, Germany diluted with 970 mL
water) was administered during the uptake period.
Patients were examined in supine position. All patients
received a non-enhanced CT scan, which was acquired
with the following parameters: 80 mA, 140 kV, 0.5 s
tube rotation, 4.25-mm section thickness. The CT scans
were acquired during shallow breathing in the head and
neck area, the thorax, and the lower abdomen and dur-
ing non-forced expiration in the upper abdomen. The
scan included the area from the head to the upper thighs.
Directly after the CT-acquisition, the PET-emission scan
was acquired with an acquisition time of 2 min per bed
position. The patient stayed in the same supine position
on the PET/CT table during the whole procedure.
Immediately after the non-ce-PET/CT, the images were
reviewed directly on the scanner console and the largest
target liver lesion was deﬁned based on the focal glucose
metabolism on the PET-images or anatomical changes
seen in the low dose CT of the metastases (43 patients,
mean SUVmax:18.1). In cases the lesion had no or
only as much FDG-avidity as the surrounding liver
tissue (e.g., post-therapeutic patients), the non-contrast
CT-images were reviewed carefully for the largest target
lesion as already demonstrated in other studies (three
patients, mean SUVmax: 2.0) [3]. Then, the intravenous
contrast injection was started by injecting a total dose of
90 mL contrast media (Ultravist 370, Bayer Schering
Pharma, Germany); the first part: for the CT-perfusion,
the second part for completion of routine ce-CT for
fusion with the PET-data. Ninety milliliter contrast
media represents the standard dose for imaging of the
abdomen in standard ce-CT and ce-PET/CT in our
department. First, 40 mL of contrast media (Ultravist
370, Bayer Schering Pharma, Germany) with a flow of
4 mL/s was applied via a cubital vein for 10 s with an
automated power injector (Vistron, Medrad, Indianola,
PA) at the above determined position in the region of the
liver. This represents the default protocol as suggested by
the vendor. After a 5-s delay, the perfusion data were
acquired for 35 s in the area of interest (1 s rotations
time, cine duration 35 s, 8 slices, 5-mm slice thickness,
80 mA, 80 kV). Breathing was not suspended, but the
patients were instructed prior to the scan to breath very
shallowly to minimize respiratory excurses as already
proposed in other studies, which investigated breathing-
sensitive abdominal lesions [17]. By this technique, an
anatomical cranio-caudal coverage of 4 cm was achieved
for the perfusion scan of the liver target lesion. Directly
after the perfusion-scan, a second bolus of another
50 mL of contrast media (Ultravist 370, Bayer Schering
Pharma, Germany) was applied, again with 4 mL/s
followed by a saline flush of 30 mL. After a delay of 70 s
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(portal-venous phase), the routine ce-CT (120 kV, dose
modulated tube current up to 700 mA, 2.5 mm, pitch
1.375:1, 13.75 mm/rotation speed) was applied breath
hold (Fig. 1). Total data acquisition time for the whole
procedure ranged between 18–22 min. The initially
acquired non-enhanced low-dose CT-data (4.25-mm
slices) was used for attenuation correction, and images
were reconstructed by using a standard fully 3 D-iterative
algorithm (ordered subset expectation maximization).
For image co-registration and analysis, all reconstructed
images (non-enhanced CT, ce-CT, CT-perfusion images)
were then transferred to a commercially available
workstation (Advantage Workstation, 4.4, GE Healt-
care, Milwaukee, WI, USA), where image data can be
evaluated in all three planes as a single procedures and in
a co-registered mode. Also CT-perfusion data were
evaluated on the same platform using a commercially
available perfusion software, which uses the deconvolu-
tion method to calculate the perfusion values. (CT-Per-
fusion 3, Body-Protocol, see also image evaluation
below).
Image evaluation
CT-perfusion evaluation. CT-perfusion data were evalu-
ated by one dual-board certiﬁed nuclear medicine phy-
sician/radiologist using the default body-protocol of the
commercially available CT-perfusion software as above
mentioned. A threshold of 20–400 HU was deﬁned for
soft tissue visualization. The arterial input was deﬁned by
a circular ROI of 40 mm2 size in the aorta, which was
displayed within the perfusion volume. The consecutive
time enhancement curve and the parametric imaging
maps for BF (mL/100 mg tissue/min), BV (mL/100 mg
tissue), and MTT (s) were automatically calculated by
the software. The permeability surface was not calculated
in this study because the study protocol is too short for
adequate permeability calculation.
A freehand ROI deﬁned by the margin of the target
liver metastases was placed in every slice of the perfusion
volume (4-cm detector coverage, 5-mm slice thickness). A
second ROI (when possible, equally sized and shaped as
the ROI, which was used for the liver metastases evalu-
ation, otherwise: standard 250 mm2 ROI) was positioned
the non-diseased liver parenchyma (normal liver paren-
chyma) in every slice, too. The 250 mm2 ROI was used in
cases when there was not enough space for an equally
sized and shaped as the ROI, for example in the lower
parts of liver segment six or at the edges of the liver.
CT-perfusion data of the non-diseased liver paren-
chyma and CT-perfusion data of the liver metastases
were calculated in every slice. Mean values for all per-
fusion data (liver metastases and non-diseased (normal)
liver parenchyma) were calculated and compared to
evaluate the differences in perfusion behavior between
metastases and non-diseased liver parynchema. Fur-
thermore, the CT-perfusion data of the pre-therapeutic
subgroup were compared versus the post-therapeutic
subgroup (see ‘‘Patients’’ section above).The total effec-
tive radiation dose was estimated for CT (DLP 9
0.017 mSv/cGy/cm) as previously suggested [18].
PET-data evaluation. PET-data were evaluated by one
dual-board certiﬁed nuclear medicine physician/radiolo-
gist. A cubic volume of interest (VOI) was placed over
the target liver metastases in the PET-images. The VOI
automatically calculated the Standard Uptake Value
(SUVmax, SUVmean), TLG as well as the volume of the
lesion (PETvol) based on a deﬁned PET-threshold. The
PET-threshold was chosen based to the non-diseased
liver tissue. All evaluated PET-values were correlated
with the CT-perfusion data of the liver metastases to
demonstrate possible correlations or interactions.
CT-data evaluation. To evaluate and to demonstrate
the clinical adequacy of the divided contrast media
protocol for routine clinical PET/CT-evaluation, mea-
surements (Hounsﬁeld Units) of the aorta, the portal
vein, one liver vein, and a standard 250 mm2 ROI in the
Fig. 1. The course of the
examination protocol. The non-
enhanced PET/CT is acquired
first. After review of the images,
the position of the target lesion
was defined and the perfusion
volume was adjusted
accordingly. Directly after the
acquisition of the perfusion data,
the routine ce-CT was
conducted.
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liver parenchyma were performed. The values were
compared with the current literature concerning opti-
mized contrast-media CT-protocols.
Statistical analysis
To demonstrate the differences between the liver
lesion and the surrounding, non-diseased (normal) liver
parenchyma the two-sided paired t-test was used. A
P-value of 0.05 was considered significant. Differences of
means, standard error of differences of means as well as
95% confidence intervals were calculated, too.
Generally, for relatively small samples, we always
cross check results of parametric signiﬁcance tests with
more robust non-parametric tests and therefore, two
tests were used for all perfusion parameters. The signif-
icant results, which are reported arised from paired
t-tests. The Wilcoxon signed rank test produced analo-
gous results and, thus, under such circumstances it makes
sense to report t-test results because these are in-line with
means of differences and its confidence intervals, which
are presented too. Thus, no Wilcoxon’s signed rank test
results are presented. The correlation between all
CT-perfusion data and all evaluated PET-data were
calculated using Spearman’s rho, a non-parametric rank
correlation coefficient. However, this was not done be-
cause the variables were not normally distributed, but it
means that we wanted to relax the normality assumption.
Last, to demonstrate differences in CT-perfusion and/or
PET-data between pre- and post-therapeutic patients, the
Mann–Whitney test was used.
Statistical analyses were performed with SPSS statis-
tical software (Version 16.0.1, SPSS Inc, Chicago, IL).
Results
Feasibility and image quality of the combined
CT-perfusion-PET/CT-protocol
Patients were included between May 2007 and June 2008.
All 46 patients tolerated the PET/CT-procedure with
integrated CT-perfusion well. Whole-body non-ce-PET/
CT data as well as clinical ce-PET/CT could be evaluated
for routine clinical staging in all 46 patients. CT-perfusion
data could be evaluated in all but one patient. By using
the contrast media for the CT-perfusion part as well as for
the ceCT-part, adequate image quality for the ce-CT as
well as perfusion parameters (see next section) could be
obtained in one single imaging procedure (Table 1,
Fig. 2).
Based on the ﬁxed CT-parameters for the acquisition
of the perfusion data, the total effective radiation dose
was 5 mSv in all patients.
CT-perfusion evaluation
Perfusion data could be obtained in 45 patients (98%). In
one patient, perfusion data of the metastases could not
be evaluated due to breathing artefacts (highly volatile
breathing during the perfusion data acquisition). Table 2
demonstrates the perfusion values of the liver metastases
versus the perfusion values of the normal liver tissue.
A statistically signiﬁcant difference was found when
comparing the BF (difference of mean: 18.2, P < 0.001,
standard error of difference of mean: 3.6, 95% CI:
10.9–25.5) and MTT (difference of mean: -5.7,
P < 0.001, standard error of difference of mean: 0.7,
95% CI: -7.2 to -4.3) of the liver metastases versus
normal liver parenchyma.
Overall correlation of CT-perfusion data
and PET-data
All perfusion data (BF, BV, MTT) were correlated with
all acquired PET-parameter (SUVmax, SUVmean, TLG
and PETvol). Statistically signiﬁcant relations could be
demonstrated for BF and SUVmax (Spearman’s rho:
0.54, P < 0.001), for BF and SUVmean (Spearman’s
rho: 0.41, P = 0.005), and for BF and TLG (Spearman’s
rho: 0.35, P = 0.02) (Fig. 3). Statistically significant
inverse relations could be also demonstrated for MTT
and SUVmax (Spearman’s rho: -0.40, P = 0.006), for
MTT and PETvol (Spearman’s rho: -0.34, P = 0.02),
and MTT and TLG (Spearman’s rho: -0.37, P = 0.02).
Finally, statistically significant correlations were found
for BV and SUVmax (Spearman’s rho: 0.38, P = 0.01)
and for BV and SUVmean (Spearman’s rho: 0.33,
P = 0.03).
Table 1. The measured Hounsfield units (HU) in different vessels and the liver parenchyma to demonstrate adequacy of the integrated contrast
protocol. Hounsfield units are displayed as mean, median, as well as the maximal and the minimal HU (range)
Portal max Portal average Aorta max Aorta average Hep vein max Hep vein average Liver max Liver average
Mean 181.0 135.4 172.3 133.2 175.0 134.7 134.8 100.2
Median 179.0 130.0 170.5 126.5 167.5 134.0 135.0 100.5
Minimal 115.0 91.0 129.0 64.0 117.0 70.0 86.0 39.0
Maximal 402.0 202.0 225.0 185.0 279.0 211.0 192.0 152.0
Portal max/average, maximal and average HU measured in the portal vein
Aorta max/average, maximal and average HU measured in the aorta
Hep vein max/average, maximal and average HU measured in one hepatic vein
Liver max/average, maximal and average HU measured in the standard 250 mm2 ROI in the liver parenchyma
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Comparison of pre-therapeutic versus post-
therapeutic patients (subgroup)
Table 3 demonstrates the CT-perfusion values as well as
the PET-data of patients with pre-therapeutic liver
metastases (n = 18) and patients with post-therapeutic
liver metastases (n = 15, non-evaluable in one patient).
Statistically significant differences could be demonstrated
when comparing pre- and post-therapeutic MTT
(P < 0.05) while none of the PET-data showed any sta-
tistically significant difference.
Discussion
Our study demonstrates the feasibility of an integrated
CT-perfusion protocol into a ce-PET/CT examination
without use of additional contrast compared to a stan-
dard ce-PET/CTin a clinical routine environment. The
combined protocol proved to be robust as the clinical
cePET/CT could be evaluated in all patients and all
cePET/CT’s demonstrated adequate image quality. Per-
fusion data could be evaluated in all but one patient.
First clinical experiences when comparing CT-perfusion
data and PET-data are showing partial correlations be-
tween CT- and PET-parameters.
General considerations
Several issues have to be addressed when implementing a
CT-perfusion protocol into a whole-body FDG-PET/
CT-protocol. Such a new imaging concept should, ide-
ally, provide additional useful parameters at equal or
only minimally higher procedure complexity at the same
image quality. The non-ce-PET/CT images had to be
reviewed prior to the contrast administration at the PET/
CT-console to deﬁne the position for the perfusion scan,
which took on average 2 min. Thus, the in-room-time of
our protocol was only slightly longer than for standard
PET/CT-procedures. However, it is deﬁnitively less time-
consuming than a multi-step approach where the clinical
ce-PET/CT is performed ﬁrst and the patient has to be
examined twice because CT-perfusion is still considered a
research examination.
Thus, such a protocol may represent a psychological
and physical advantage when considering the burden set
upon the patient by different imaging procedure but
providing at the same time dedicated research data for
further evaluation. Overall, there are only minor work-
ﬂow challenges to be solved, because the physician has to
be available at the scanner console to deﬁne the position
of the target lesion. Since the physician has to be at the
scanner for the contrast-media application in our insti-
tution anyway, there is only additional physician time
required concerning the acquisition of the perfusion.
Regarding the additional radiation dose introduced
by the perfusion part, an addition of 5 mSv for the
CT-perfusion part might be an acceptable additional
dose to 18–22 mSv for the entire ce-PET/CT protocol in
an oncological patient population [19].
Speciﬁc technical considerations
Most of the available CT-perfusion studies were con-
ducted with a 2-cm ﬁeld-of-view (FOV) and thus,
resulting perfusion data are only give a relatively small
insight into the tumor’s perfusion behavior [1, 17, 19, 20].
Fig. 2. The image quality of the divided contrast protocol in
ce-CT (A) and ce-PET/CT (B). The aorta and portal vein
(white double-arrow) as well as liver parenchyma and small
liver vessels (transparent gray arrow) show adequate image
quality. New metastases at the resection site after hemihep-
atectomy (lateral white arrow).
Table 2. The mean perfusion values of the malignant liver lesion
compared to the non-diseased liver parenchyma
Mean N Standard
deviation
Standard
error mean
CTL-BF 37.8 45 26.5 3.9
CTN-BF 19.6 45 14.2 2.1
CTL-MTT 13.2 45 4.0 0.6
CTN_MTT 18.9 45 5.2 0.8
CTL-BV 4.6 45 1.7 0.3
CTN-BV 4.6 45 2.3 0.3
Significant differences were noted between BF and liver parenchyma as
well as MTT and liver parenchyma
CTL-BF/MTT/BV/, perfusion parameters of the malignant lesion
CTN-BF/MTT/BV/, perfusion parameters of the non-diseased liver
parenchyma
N = evaluated patient number (overall 46 patients, one drop-out as
described in the ‘‘results’’ section
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As our PET/CT scanner provides a 4-cm detector range
(64-slice CT-scanner), our perfusion data might give a
larger insight into the perfusion behavior and the mean
perfusion parameter might reflect more stable values.
Recently, introduced scanner techniques like the 320-
slice CT scanner and scanners with ‘‘shuttle-mode’’ are
probably able to overcome the limitation of a small
FOV. However, they are expected to increase radiation,
too, and are not yet available in a combined PET/CT
scanner. Although Meijerink et al. already introduced a
protocol to cover the whole liver with a 64-slice scanner,
this protocol significantly increased the radiation dose up
to 24 mSv just for the perfusion scan and is therefore
adding significant radiation to the patient [21]. Addi-
tionally, the presented total liver perfusion protocol was
found to be time-consuming, and in 14/20 cases, the
time–density curves were considered unacceptable to
calculate the perfusion maps and had therefore to
undergo compensation image fusion and registration.
We did not suspend breathing for several reasons.
First, to maximize patients’ comfort. However, the
patients were instructed prior to the scan to breathe very
shallowly to minimize respiratory excurses. Other studies
have already used such an approach in other breathing-
sensitive and movement-sensitive abdominal lesions, too
[17]. Furthermore, breathing protocols have been already
recommended earlier as clinically adequate when used in
conjunction with PET-acquisitions [22]. Finally, in an
initial trial phase, we experienced that a significant
number of our oncological, and therefore physically
limited, patients could not hold the breath long enough
for the perfusion scan and that in this case, we had much
more breathing artefacts by the end of the perfusion scan
due to overcompensating wheezing. Overall, it is
Fig. 3. Fifty y/o male patient
with history of a colorectal
cancer and hepatic metastases
1 week after chemotherapy. The
ce-CT (A) shows partly necrotic
areas in this large liver
metastases, the corresponding
PET/CT (B) shows high FDG-
avidity in the peripheral vital and
centrally necrotic metastases.
Corresponding parametric
perfusion images shows the
metastases of the patient as
blood flow (C) and blood volume
image (D). E and F showing the
corresponding images for mean
transit time and permeability
surface. The metastases of this
patient showed a high FDG-
avidity (SUVmax: 11.5) and high
perfusion values (BF: 47.4 mL/
100 g tissue/min, BV: 6.2 mL/
100 g tissue, MTT: 11.4 s, PS:
20.8 mL/100 g tissue/min).
SUVmax/mean, PETvol/TLG:
PET-data of the liver lesions.
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certainly controversial how much more accurate a
breathhold approach might be, especially considering
that there are no studies available comparing both ap-
proaches with an accepted gold-standard (e.g., flow-
cytometry).
No signiﬁcant differences in image quality could be
detected when comparing our contrast protocol (ﬁrst
injection for the perfusion, second injection for comple-
tion for the diagnostic cePET/CT) and the HU given in
the current literature [23]. Most of the other studies used
a single injection to conduct the perfusion study and a
potential consecutive diagnostic scan [1, 4, 17]. The
rationale to use a divided protocol in our study was to
use the default protocol (40 mL at 4 mL/s) as recom-
mended by the vendor, to acquire a clinically adequate
CT-component within the PET/CT for evaluation of
other distant metastases and to have a combined perfu-
sion PET/CT in one step without significant disruption
of the clinical routine.
Speciﬁc considerations concerning comparison
of perfusion and PET-data
To date, several body-perfusion studies have been per-
formed for different tumor entities, but most of them
have been conducted for lung cancer patients and expe-
rience with CT-perfusion of the liver is limited [3, 20].
There are recent studies, which also integrated CT-per-
fusion into PET/CT, however, in different body com-
partments [2, 5, 6].
In the study of Miles and co-workers, no general
correlation (only for small tumors) between tumor size
and SUV and SPV (standardized perfusion value) was
found, while in our study a statistically signiﬁcant cor-
relation between the tumor volume (PETvol) and BF and
MTT was detected. In another study by Groves et al. in
patients with primary breast cancer, a correlation
between SUV and perfusion values normalized to cardiac
output was found, whereas no correlation between SUV
and tumor perfusion or permeability was found [24].
However, there are major differences to be consid-
ered. Our correlation is based on a larger patient popu-
lation with different malignant liver lesions, whereas
Miles and co-workers and Groves and co-workers eval-
uated smaller patient populations with NSCLC and
breast cancer and thus, making a reasonable comparison
almost impossible. In a recent study in head and
neck cancers, differences between tumor and normal
surrounding tissue could be demonstrated [5].
The two studies that evaluated (partly) liver lesions
also found signiﬁcant differences between the perfusion
values of liver lesions and the normal liver parenchyma
[3, 20]. However, as demonstrated in other tumor enti-
ties, we could not detect significant differences of BV and
the liver lesions and the surrounding parenchyma [1].
One reason for the non-significant differences in BVs
might be the different sizes of the measured ROI’s.
Whenever possible, the ROI measuring the normal liver
parenchyma had the same size and shape as the ‘‘tumor
ROI’’. However, this was not possible in all slices of the
perfused volume, for example, in the basal parts of liver
segment six or the edges of the liver. Sabir et al. and
several other authors demonstrated that perfusion
parameters (BF and MTT) are showing the closest cor-
relation with laser-flowmetry, histopathology, and clini-
cal outcome and therefore, those seem to represent the
most reliable parameter [25–27].
Interestingly, highest correlations were detected
between BF and MTT and SUVmax. This might be due
to the fact, that cells, which are supplied best by BF, are
able to have a high metabolism. Both parameters also
correlate with the TLG, a combined ‘‘metabolic-volu-
metric’’ parameter, which is considered to represent a
more accurate tumor burden [28–30]. One explanation
for this could be that a high tumor volume (one part of
the TLG) of viable tumor cells (SUV, second part of the
TLG) requires a higher flow. However, this remains to be
proven since there is no explanation available in the
current literature and no other comparison with micro-
vessel density or flowmetry and TLG has been conducted
so far.
There was only a signiﬁcant difference between pre-
and post-therapy MTT detectable in our patient popu-
lation. Values, e.g., for BF and PETvol were different,
too, but showed higher standard deviations, which might
be the reason that they did not achieved signiﬁcant dif-
ference levels. We do not have pre- and post-therapy
comparisons in the same patients, patients had further-
more different chemotherapy schemes and thus, those
results have to be interpreted with caution. However,
they might give an indication that perfusion parameters
Table 3. The comparison of the mean values of perfusion values and
PET-data in the subgroup of patients with colorectal carcinoma
Therapy Mean Standard
deviation
Standard
error mean
CTL-BF Post 40.3 26.6 6.9
Pre 28.8 10.8 2.6
CTL-MTT Post 12.5 3.8 1.0
Pre 15.0 3.2 0.8
CTL-BV Post 4.2 1.5 0.4
Pre 4.7 1.6 0.4
SUVmax Post 6.0 2.7 0.7
Pre 7.0 4.3 1.0
SUVmean Post 3.5 1.1 0.3
Pre 4.0 1.6 0.4
PET-vol Post 157.3 371.9 99.4
Pre 46.7 93.9 22.1
PET-TLG Post 5.3E5 1.1E6 3.01E5
Pre 2.2E5 4.8E5 1.1E5
Significant differences were detected between pre-and post MTT
Therapy, pre/post: mean values of the perfusion values and PET-data
pre-therapy and post-therapy
CTL-BF/MTT/BV/, CT-based perfusion parameters of the liver lesions
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can add important information additionally to PET-
parameters.
Controversials/limitations
Several issues are discussed controversially in the current
literature. Although we already used a 4-cm FOV for the
perfusion, we still do not have a full tumor coverage in all
tumors—which would be desirable. Other perfusion pro-
tocols have been already introduced but have their draw-
backs, too (see above). Another topic is the shape of the
ROI for perfusionmeasurement. Goh et al. [17] found that
a ROI outlining the tumor is the currently most appro-
priate method to provide consistent measurements within
a study. Hence, measurements from the edge, the center,
and the entire tumor volume would add more accuracy in
perfusion measurements but are time consuming and are
adding additional complexity. Since there is no software-
based auto-detection yet available, we chose the outlining
approach. We did not have histopathological verification
of every liver lesion, however, this is not possible and
ethically not justifiable in a routine clinical setting. The
breathing approach in our study might be controversially,
too (see above). However, since other studies already used
a breathing approach in a breathing sensitive area, too,
such a protocol might be considered adequate in a clinical
routine setting. There is currently no consensus in which
way and how much integrated PET/CT-perfusion might
contribute to therapeutic decisions in clinical routine.
Hence, larger prospective studies are needed to define the
role of perfusion parameters in therapeutic management.
However, the here presented results might serve as a pri-
mer for further investigations.
Conclusion
This is a feasibility report on successful technical inte-
gration of a combined CT-perfusion/PET/CT-protocol
without the use of additional contrast media compared
to a standard ce-PET/CT. Several questions concerning
the partial correlations between perfusion parameters
and PET-data remain open and have to be investigated
in further studies. Overall, the evaluated protocol might
expand the insight and understanding in tumor physiol-
ogy with acceptable additional radiation burden to the
patient but providing important additional research
information in one step.
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